iCo Therapeutics Inc (CVE:ICO) Director William Wasyl Jarosz purchased 273,556 shares of iCo Therapeutics stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of C$0.35 per share, with a total value of C$95,744.60. Following the completion of the transaction, the director now owns 976,556 shares of the company’s stock, valued at approximately C$341,794.60.
Shares of ICO stock opened at C$0.05 on Wednesday. The stock has a 50 day moving average of C$0.04 and a 200 day moving average of C$0.05. The stock has a market cap of $7.69 million and a P/E ratio of -3.00. iCo Therapeutics Inc has a twelve month low of C$0.02 and a twelve month high of C$0.14.
iCo Therapeutics Company Profile
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.